Early Beta Blocker Administration in STEMI Patients With SCAI B Status

Condition(s) studied

Investigational drug(s) / intervention(s)

Metoprolol (MET): Administration of metoprolol 25 mg twice daily

Plcacebo: Administration of matching placebo

Study summary

This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.

When patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups.

During the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations.

The main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.

Eligibility

Primary outcome measure(s)

• Number of patients progressed from SCAI B to SCAI C — 3 days from enrollment
  number of patients who progressed from SCAI B to SCAI C as measured by - Serum lactate levels \> mmol/L urinary output \> 0.5 ml/kg/hour slow capillary filling Change in mental status

Trial sites (1)

More Tel-Aviv Sourasky Medical Center trials in Israel